Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174043 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01174043 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 11 participants.
The verdict
NCT01174043, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This research study is looking for patients with newly diagnosed acute myeloid leukemia (AML), AML that has returned (relapsed), or it has not responded adequately to previous treatments. Treating certain patients with chemotherapy may not be to their benefit or may cause more harm than benefit. The purpose of this study is to find out what effects (good and bad) erlotinib has on patients and their AML.
Interventions
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01174043
The ClinicalTrials.gov registry entry for NCT01174043 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erlotinib is the first listed.
NCT01174043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01174043 about?
NCT01174043 is a clinical study titled "Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia". This research study is looking for patients with newly diagnosed acute myeloid leukemia (AML), AML that has returned (relapsed), or it has not responded adequately to previous treatments. Treating certain patients with chemotherapy may not be to their benefit or may cause more harm than benefit. The...
What is the current status of trial NCT01174043?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2010-07. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01174043?
The interventions under investigation include: Erlotinib (DRUG).
Who is sponsoring clinical trial NCT01174043?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.